Literature DB >> 9276028

CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line.

J L Fendrick1, I Konishi, S M Geary, T H Parmley, J G Quirk, T J O'Brien.   

Abstract

Evidence is presented suggesting that CA125 is a serine and/or threonine phosphoprotein and that its secretion from the human amnion WISH cell line is closely linked to its phosphorylation. It is also indicated that regulation of CA125 secretion requires protein(s) tyrosine phosphorylation. WISH cells treated with a tyrosine phosphatase inhibitor, vanadate/ H2O2, resulted in increased levels of CA125 secretion. Exposure of vanadate-treated cells to epidermal growth factor further enhanced this secretory activity. Immunohistochemistry of vanadate-treated cells resulted in a substantial increase in not only cytoplasmic tyrosine phosphoproteins but also in membrane-associated CA125 when stained with the PY20 anti-phosphotyrosine and M11 anti-CA125 monoclonal antibodies, respectively. M11 immunoprecipitation of CA125 from cells labelled with [32P]-orthophosphate was analyzed by SDS-PAGE and autoradiography. Immunoprecipitates from cell lysates demonstrated that a phosphoprotein of > 200 kD was isolated and immunoreacted with both the OC125 and M11 anti-CA125 monoclonal antibodies by Western blotting. CA125 immunoprecipitated from vanadate-treated cells showed a marked increase in cell-associated CA125 phosphorylation. Although CA125 could be immunoprecipitated from WISH cell media incubated with [32P]-orthophosphate in the presence or absence of vanadate as detected by Western blotting, autoradiographic analysis of the Western blots revealed no [32P]-labelled CA125 co-migrating with the 200-kD plus molecule detected by M11. When the PY20 anti-phosphotyrosine monoclonal antibody was used as the probe, no tyrosine-phosphorylated CA125 was detected in cell lysates.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9276028     DOI: 10.1159/000218041

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  8 in total

1.  Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.

Authors:  Thapi Dharma Rao; Kay J Park; Peter Smith-Jones; Alexia Iasonos; Irina Linkov; Robert A Soslow; David R Spriggs
Journal:  Appl Immunohistochem Mol Morphol       Date:  2010-10

Review 2.  Membrane-tethered mucins have multiple functions on the ocular surface.

Authors:  Bharathi Govindarajan; Ilene K Gipson
Journal:  Exp Eye Res       Date:  2010-03-16       Impact factor: 3.467

3.  Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.

Authors:  Nathalie Scholler; Barbara Garvik; Martha Hayden-Ledbetter; Toni Kline; Nicole Urban
Journal:  Cancer Lett       Date:  2006-05-04       Impact factor: 8.679

4.  MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells.

Authors:  I Lakshmanan; M P Ponnusamy; S Das; S Chakraborty; D Haridas; P Mukhopadhyay; S M Lele; S K Batra
Journal:  Oncogene       Date:  2011-07-25       Impact factor: 9.867

Review 5.  Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy.

Authors:  Srustidhar Das; Surinder K Batra
Journal:  Cancer Res       Date:  2015-11-02       Impact factor: 12.701

Review 6.  Membrane-associated mucins of the human ocular surface in health and disease.

Authors:  Rafael Martinez-Carrasco; Pablo Argüeso; M Elizabeth Fini
Journal:  Ocul Surf       Date:  2021-03-26       Impact factor: 6.268

7.  Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments.

Authors:  Srustidhar Das; Prabin D Majhi; Mona H Al-Mugotir; Satyanarayana Rachagani; Paul Sorgen; Surinder K Batra
Journal:  Sci Rep       Date:  2015-06-05       Impact factor: 4.379

Review 8.  MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.

Authors:  Mildred Felder; Arvinder Kapur; Jesus Gonzalez-Bosquet; Sachi Horibata; Joseph Heintz; Ralph Albrecht; Lucas Fass; Justanjyot Kaur; Kevin Hu; Hadi Shojaei; Rebecca J Whelan; Manish S Patankar
Journal:  Mol Cancer       Date:  2014-05-29       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.